Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that data from pre-clinical and clinical studies demonstrating the latest understanding of Tumor Treating Fields (TTFields) will be presented and published as part of the 2015 Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 29 to June 2, 2015.

The clinical data will include a presentation of results from the EF-14 Phase III trial of TTFields in patients with newly diagnosed glioblastoma. The EF-14 trial met its pre-specified endpoints of progression-free and overall survival at the pre-specified interim analysis. The current presentation will include, for the first time, data on all 700 patients who participated in the trial.

Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma: First report of the full dataset of the EF14 randomized phase III trial
Presenter: Roger Stupp, MD, University Hospital Cancer Center at the University of Zurich, Zurich, Switzerland
Date and Time: Tuesday, June 2 from 8:00 – 8:12 AM
Abstract: 2000
Session: Central Nervous System Tumors
Room: S404

Several additional abstracts have been accepted for publication in conjunction with ASCO 2015 and can be found online at: http://abstract.asco.org.

Survival Benefit of Tumor Treating Fields Plus Stereotactic Radiosurgery for Malignant Gliomas
Principal Author: Eric T. Wong, MD, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Abstract: e13029

PANOVA: A pilot study of TTFields concomitant with gemcitabine for front–line therapy of advanced pancreatic carcinoma
Principal Author: Fernando Rivera, MD, PhD, Hospital Universitario Marques de Valdecilla, Santander, Spain
Abstract: e15269

NovoTTF-100A system (tumor treating fields) transducer array layout planning for glioblastoma: Results of a NovoTAL system user study
Principal Author: Aafia Chaudhry, MD, Novocure, New York, New York
Abstract: e13029

Transducer array layout optimization for treating lung-based tumors with TTFields
Principal Author: Ze’ev Bomzon, PhD, Novocure, Haifa, Israel
Abstract: e18503

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.

Approved Indication

The US FDA has approved the TTFields therapy delivery system, Optune (previously known as the NovoTTF-100A System), for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed GBM, following histologically or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301.

About Novocure

Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.